Transforming cell and gene therapy commercialization starts here. https://ow.ly/Se8U50U9smP Join Jennifer (Goldenberg) Klarer, M.Sc.Eng., an industry thought leader from The Dedham Group, at ASH 2024 in San Diego, December 7-10. Explore our innovative strategies for maximizing market access and achieving your commercialization goals. Secure your time with Jennifer now! #ASH #ASH24
The Dedham Group’s Post
More Relevant Posts
-
NEWS ALERT: The first patient has been dosed in our TN-401 gene therapy in the RIDGE-1 Phase 1b clinical trial, marking a significant step forward in our journey to transform care for individuals living with PKP2-associated #ARVC. This milestone reflects our unwavering commitment to discover, develop and deliver potentially curative therapies that address the underlying drivers of #heartdisease. Read more: https://lnkd.in/eqfwvcQU #HCM #GeneTherapy #Biotech
-
-
Please share the links for all-- your knowledge is also of use for first time biotech founders also try to move therapies forward and may have more in common with a foundation than you might expect.... #EveryoneCanContribute #NoMoreDiseaseInducedMorbidityAndMortality #MissionDrivenFoundersTryingToAdvanceTherapiesAndCures #YouHaveFoundRoutesThatManyCanLearnFrom....
Our FOXG1 Research Foundation gene therapy program progresses: We had a highly productive INTERACT meeting with the FDA resulting in a streamlined and efficient nonclinical path to IND. We look forward to our continued collaborative dialog with FDA and work toward our pre-IND meeting. We will continue to document all our learnings into a blueprint for other patient foundations running drug development to learn from! #curefoxg1 #RareAsOne
-
-
Cell and Gene Therapy Catapult has once again published its GMP Report and we are delighted to be included for the first year as an MHRA (IMP) licensed facility for multifunctional cell and gene therapy manufacturing! It's clear the UK manufacturing landscape is strong with 6 commercially licensed products now being produced in the UK and significant growth in the CGT workforce. Today we celebrate the successes of the entire UK Advanced Therapy community 👏
The Cell and Gene Therapy Catapult has released its Good Manufacturing Practice (GMP) Report 2024 which highlights continued growth in the UK's manufacturing infrastructure for #AdvancedTherapies. Key findings from the report, which is based on a survey of organisations in the UK, include: - Six commercially licensed products now produced in the UK ✔️ - An increase in licensed facilities 🏭 - An increase in full-time employees 🥼 Read the report: https://lnkd.in/eeTz7_kP #CellTherapy #GeneTherapy #ATMPs
-
-
Exciting news! 🔊 Cell and Gene Therapy Catapult has released its 2024 GMP Report yesterday! 🧬 This report highlights exciting progress in the industry, showcasing growth in licensed products, expanded facilities, and specialist employees! 🏭🥼 These advancements are essential as we move towards the wider adoption of cell and gene therapies, ensuring the UK remains a leader in global manufacturing. Read the full report below ⬇️⬇️⬇️ #CellTherapy #GeneTherapy #Innovation
The Cell and Gene Therapy Catapult has released its Good Manufacturing Practice (GMP) Report 2024 which highlights continued growth in the UK's manufacturing infrastructure for #AdvancedTherapies. Key findings from the report, which is based on a survey of organisations in the UK, include: - Six commercially licensed products now produced in the UK ✔️ - An increase in licensed facilities 🏭 - An increase in full-time employees 🥼 Read the report: https://lnkd.in/eeTz7_kP #CellTherapy #GeneTherapy #ATMPs
-
-
TOMORROW // Important considerations and challenges during the Investigational New Drug (IND) application process, with a focus on cell and gene therapy, here 👇 Live webinar | Register now: https://bit.ly/3TrVtbm
-
-
Yet again, the data speaks for itself...there is clear confidence in the UK's ATMP manufacturing capability and infrastructure as it continues to grow year-on-year. With the skilled workforce growing by 7%, the cleanroom footprint growing by 12% and in-house QC increasing by 15% And this growth is an outcome of some great UK manufacturing successes this year: - RoslinCT manufacturing the world's first CRISPR-edited therapy for Vertex Pharmaceuticals (with the Medicines and Healthcare products Regulatory Agency giving the world's first approval) - Autolus Therapeutics having their BLA accepted and achieving licensure of their own commercial manufacturing facility - Adaptimmune having their BLA accepted - Quell Therapeutics expanding their manufacturing in the newly licensed eXmoor Pharma facility And various other successes which I've inevitably missed (sorry to anyone I've missed out!) Innovate UK Department for Science, Innovation and Technology Department for Business and Trade
The Cell and Gene Therapy Catapult has released its Good Manufacturing Practice (GMP) Report 2024 which highlights continued growth in the UK's manufacturing infrastructure for #AdvancedTherapies. Key findings from the report, which is based on a survey of organisations in the UK, include: - Six commercially licensed products now produced in the UK ✔️ - An increase in licensed facilities 🏭 - An increase in full-time employees 🥼 Read the report: https://lnkd.in/eeTz7_kP #CellTherapy #GeneTherapy #ATMPs
-
-
Cell and Gene Therapy Catapult (CGT) has released its Good Manufacturing Practice (GMP) Report 2024, highlighting continued growth in manufacturing infrastructure for advanced therapies. As part of the Innovate UK Catapult Network, CGT Catapult plays a crucial role in driving the growth of next-generation therapies that can transform patient care and contribute to national economic growth.
The Cell and Gene Therapy Catapult has released its Good Manufacturing Practice (GMP) Report 2024 which highlights continued growth in the UK's manufacturing infrastructure for #AdvancedTherapies. Key findings from the report, which is based on a survey of organisations in the UK, include: - Six commercially licensed products now produced in the UK ✔️ - An increase in licensed facilities 🏭 - An increase in full-time employees 🥼 Read the report: https://lnkd.in/eeTz7_kP #CellTherapy #GeneTherapy #ATMPs
-
-
ICYMI: The Cell and Gene Therapy Catapult (CGT) has released its 2024 Annual Review 🦠🔬. This report highlights significant milestones made by the CGT Catapult and the UK’s advanced therapy medicinal products (ATMP) industry. Key achievements from the past year include: ➡️ 79 companies collaborated with on ATMP innovation (56% of which are UK SMEs) ➡️ £656m in financing raised by their UK collaborators (including £453m by its collaborators in Stevenage) ➡️ 11 companies supported that are conducting clinical trials As part of the Innovate UK Catapult Network, the CGT Catapult plays a crucial role in driving the growth of next-generation therapies that can transform patient care and contribute to national economic growth. Read the report here: https://lnkd.in/eJetPtsy...
'Advanced therapies have potential to be life-changing for individuals and their families, significantly reduce costs for healthcare systems and bolster the UK economy. With coherent and concerted action, the UK can take the lead in demonstrating how to harness the potential of this sector' - Ian McCubbin CBE, Chairman, CGT Catapult. ➡️ https://ow.ly/h9uM50Tg7It Today the Cell and Gene Therapy Catapult publishes its Annual Review 2024 which highlights the UK #ATMP industry's development and the four conditions that need to be met for its continued growth and success. Learn more ☝️ #CellTherapy #GeneTherapy #AdvancedTherapies
-
-
The Cell and Gene Therapy Catapult has released its Good Manufacturing Practice (GMP) Report 2024 which highlights continued growth in the UK's manufacturing infrastructure for #AdvancedTherapies. Key findings from the report, which is based on a survey of organisations in the UK, include: - Six commercially licensed products now produced in the UK ✔️ - An increase in licensed facilities 🏭 - An increase in full-time employees 🥼 Read the report: https://lnkd.in/eeTz7_kP #CellTherapy #GeneTherapy #ATMPs
-
-
Head of Marketing @ Cell and Gene Therapy Catapult | Innovative Marketing Communications | Building and leading high-performing teams to promote new technology and innovation in advanced therapies
🚀 Exciting news from the Cell and Gene Therapy Catapult! The release of the 2024 Good Manufacturing Practice (GMP) Report showcases the continued growth of the UK’s manufacturing infrastructure for #AdvancedTherapies #ATMPs #CellandGeneTherapy #UK
The Cell and Gene Therapy Catapult has released its Good Manufacturing Practice (GMP) Report 2024 which highlights continued growth in the UK's manufacturing infrastructure for #AdvancedTherapies. Key findings from the report, which is based on a survey of organisations in the UK, include: - Six commercially licensed products now produced in the UK ✔️ - An increase in licensed facilities 🏭 - An increase in full-time employees 🥼 Read the report: https://lnkd.in/eeTz7_kP #CellTherapy #GeneTherapy #ATMPs
-
